Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vistin Pharma ASALTS:0RAM 76 3-Year Book Growth Rate is 6.30% as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 76/100 and a GF Value™ of kr25.81 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 56.31% on this metric.
During the past 12 months, Vistin Pharma ASA's average Book Value per Share Growth Rate was 5.80% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 6.30% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 4.20% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -3.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Vistin Pharma ASA was 6.30% per year. The lowest was -12.90% per year. And the median was -3.00% per year.
Vistin Pharma ASA (LTS:0RAM) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Vistin Pharma ASA 3-Year Book Growth Rate Related Terms
LTS:0RAM vs ZTS, UTHR, VTRS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's 3-Year Book Growth Rate falls into.
Vistin Pharma ASA 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 6.30% mean?
Vistin Pharma ASA (LTS:0RAM) has a 3-Year Book Growth Rate of 6.30% as of Mar. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Vistin Pharma ASA and its competitors. According to the industry distribution chart, Vistin Pharma ASA ranks #398 out of 911 companies in the Drug Manufacturers industry, placing it in the top 43.7%.
Is Vistin Pharma ASA's 3-Year Book Growth Rate too high?
Vistin Pharma ASA's current 3-Year Book Growth Rate is 6.30%. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.80. Vistin Pharma ASA's value of 6.30% is 31.3% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #398 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's 3-Year Book Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #398 out of 911 companies for 3-Year Book Growth Rate. This puts Vistin Pharma ASA in the upper half of its industry. The industry median 3-Year Book Growth Rate is 4.80. Vistin Pharma ASA's value of 6.30% is 31.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.80, based on 911 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current 3-Year Book Growth Rate of 6.30% is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current 3-Year Book Growth Rate is 6.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.81, compared to a current price of kr20.10 — trading 22.1% below its estimated fair value. The current 3-Year Book Growth Rate is 6.30% and 31.3% above the Drug Manufacturers industry median of 4.80. Vistin Pharma ASA's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current 3-Year Book Growth Rate is 6.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.10 is trading 22.1% below its estimated GF Value™ of kr25.81.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
3-Year Book Growth Rate: 6.30%
GF Value™: kr25.81 vs. price of kr20.10 (22.1% below fair value)
Industry Position: 31.3% above the Drug Manufacturers median (#398 of 911)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
76GF Score
Get the complete analysis for LTS:0RAM
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
